Novartis bets on mutant PI3Kα with SNV4818 acquisition to sharpen breast cancer pipeline
Novartis today announced plans to acquire SNV4818 from Synnovation Therapeutics' Pikavation subsidiary for up to USD 3 billion (USD 2 billion upfront with up to USD 1 billion in milestones) to advance a pan-mutant‑selective PI3Kα inhibitor in HR+/HER2- breast cancer; SNV4818 is designed to target mutant PI3Kα (PIK3CA) while sparing wild-type PI3Kα to improve tolerability and enable combination with hormonal therapies, addressing an unmet need in roughly 40% of HR+/HER2- patients; closing is expected in the first half of 2026.